Abstract 252P
Background
Patients with PABC have an increased frequency of germline BRCA mutations. However, the impact of these mutations on clinicopathological features and survival outcomes remains to be explored.
Methods
Patients accrued in the “Joven & Fuerte” program between August 2014 and October 2019 were analyzed. PABC was defined as breast cancer (BC) diagnosed during pregnancy or within 24 months of delivery. Patients were grouped according to BRCA mutation status. Associations between groups were explored using Fisher's exact tests. After excluding patients with stage IV BC, survival outcomes were examined with the Kaplan-Meier method and a Cox regression model was employed for group comparisons.
Results
A total of 552 women were diagnosed with BC, 42 (7.6%) of which were PABC cases. Of these, 34 had genetic test results, with 14 (41%) being BRCA mutation carriers. The median follow-up was 30 months. Overall, no significant differences were detected between carriers’ and non-carriers’ clinicopathological features, including age, primiparity, family history of cancer, pregnancy outcome, BC histological type and grade, and laterality. However, some noteworthy discrepancies were observed between both groups (Table). Regarding survival outcomes, global 2.5-year recurrence-free survival (RFS) and overall survival (OS) rates were 63% and 78%, respectively, with no significant differences according to BRCA mutation status (RFS: 72% in carriers vs. 57% in non-carriers [p=0.39]; OS: 77% vs. 78% [p=0.43]). Table: 252P
| BRCA carriers N (%) | Non-carriers N (%) | p | |
| Context of diagnosis Pregnancy Postpartum | 2 (14) 12 (86) | 6 (30) 14 (70) | 0.42 |
| Tumor subtype HR+/HER2- HR+/HER2+ HR-/HER2+ HR-/HER2- | 6 (43) 1 (7) 07 (50) | 9 (45) 3 (15) 4 (20) 4 (20) | 0.17 |
| Clinical stage I II III IV | 1 (7) 6 (43) 7 (50) 0 | 1 (5) 7 (35) 8 (40) 4 (20) | 0.40 |
| BC recurrence Yes No | 3 (21) 11 (79) | 6 (38) 10 (62) | 0.44 |
| Death Yes No | 2 (14) 12 (86) | 3 (19) 13 (81) | 0.25 |
Conclusions
Remarkably, the prevalence of germline BRCA mutations in this cohort was higher than previously reported in the literature. Some notable clinically significant differences were found, including a higher prevalence of stage IV disease and a higher recurrence rate in the non-carrier group. Future studies aimed at determining the factors that condition these associations are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.